journal article·2025

Injectable thermosensitive hydrogel-encapsulated paclitaxel liposomes enriched with miR-455-3p antagomir for dormancy therapy of salivary adenoid cystic carcinoma

Mao Li, Xu Zhang, Lin-han Zhang, Jia-rong Wang, Hua-yang Fan, Zhi-chao Dou, Xin-hua Liang, Ya-ling Tang

Journal of Materials Chemistry B· Volume 13· Issue 29
Publisher page

Abstract

Postoperative salivary adenoid cystic carcinoma (SACC) without symptoms is marked by dormant tumor cells in the primary site and metastatic organs. These cells, when reactivated, cause recurrence and metastasis. A treatment strategy that targets the "awakening" and elimination of these cells, combined with chemotherapy, could prevent and treat recurrence and metastasis. High expression of miR-455-3p were found to be crucial for SACC cell dormancy induced by serum starvation. High expression of miR-455-3p was inversely correlated with Ki-67 levels, while its reduction was linked to SACC tumor recurrence. These findings further imply that elevated miR-455-3p expression in SACC is indicative of a state of tumor dormancy. Mechanistically, a dual luciferase reporter assay provided further validation that miR-455-3p targeted GNPNAT1, regulating SACC dormancy. GNPNAT1 is downregulated in SACC tissues, and its overexpression inhibits cell dormancy and migration/invasion. An injectable, thermosensitive hydrogel designed to deliver antagomiR-455-3p via paclitaxel liposomes formed a Lip@miR hydrogel. This hydrogel "awakened" dormant SACC cells, suppressing their tumorigenic potential and leading to their eradication through sustained paclitaxel release in vivo. This approach presents a new therapeutic strategy for eliminating dormant tumor cells and reducing the risk of post-therapy cancer relapse.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Salivary Gland Tumors Diagnosis and Treatment · Salivary Gland Disorders and Functions · Hedgehog Signaling Pathway Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, Department of Pathology, West China Hospital of Stomatology, Sichuan University, Chengdu, China

State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu, China

Funding

National Natural Science Foundation of China · Key Research and Development Program of Sichuan Province

References (57)

Show source-provided references
1. Emerick · Crit. Rev. Oncol. Hemat. · 2022 · 179 · 10379210.1016/j.critrevonc.2022.103792 ↗
2. Fang · Oral Oncol. · 2022 · 130 · 10594510.1016/j.oraloncology.2022.105945 ↗
3. de Sousa · Curr. Treat. Options Oncol. · 2022 · 23 · 113510.1007/s11864-022-01001-y ↗
4. Dai · Transl. Oncol. · 2024 · 40 · 10186810.1016/j.tranon.2023.101868 ↗
5. Yang · J. Exp. Clin. Cancer Res. · 2021 · 40 · 16910.1186/s13046-021-01956-0 ↗
6. Phan · Nat. Rev. Cancer · 2020 · 20 · 39810.1038/s41568-020-0263-0 ↗
7. Rossari · Cell. Oncol. · 2020 · 43 · 15510.1007/s13402-019-00467-7 ↗
8. Sosa · Nat. Rev. Cancer · 2014 · 14 · 61110.1038/nrc3793 ↗
9. Shimizu · JCI Insight · 2019 · 4 · e12513810.1172/jci.insight.125138 ↗
10. Wei · Proc. Natl. Acad. Sci. U. S. A. · 2024 · 121 · e240750612110.1073/pnas.2407506121 ↗
11. Soureas · Trends Mol. Med. · 2023 · 29 · 84310.1016/j.molmed.2023.07.003 ↗
12. Sharma · Oncogene · 2021 · 40 · 101210.1038/s41388-020-01565-9 ↗
13. Esposito · Cancers · 2022 · 14 · 214210.3390/cancers14092142 ↗
14. Almog · Cancer Res. · 2009 · 69 · 83610.1158/0008-5472.CAN-08-2590 ↗
15. Yang · Eur. Rev. Med. Pharmacol. Sci. · 2017 · 21 · 3200
16. Hong · Theranostics · 2020 · 10 · 877110.7150/thno.46142 ↗
17. Brown · J. Oral Pathol. Med. · 2019 · 48 · 84010.1111/jop.12894 ↗
18. La · Cancer Res. · 2018 · 78 · 666610.1158/0008-5472.CAN-18-1886 ↗
19. Rupaimoole · Nat. Rev. Drug Discovery · 2017 · 16 · 20310.1038/nrd.2016.246 ↗
20. Costa · Pharmaceuticals · 2013 · 6 · 119510.3390/ph6101195 ↗
21. Bernabeu · Int. J. Pharm. · 2017 · 526 · 47410.1016/j.ijpharm.2017.05.016 ↗
22. Zhang · Cancer Commun. · 2022 · 42 · 310.1002/cac2.12225 ↗
23. Ye · Food Chem. Toxicol. · 2013 · 52 · 20010.1016/j.fct.2012.11.004 ↗
24. Yung · Mol. Pharm. · 2016 · 13 · 65310.1021/acs.molpharmaceut.5b00878 ↗
25. Zhang · J. Controlled Release · 2015 · 197 · 20810.1016/j.jconrel.2014.11.010 ↗
26. Chen · J. Nanobiotechnol. · 2021 · 19 · 5510.1186/s12951-021-00800-z ↗
27. Wang · Mol. Cancer · 2021 · 20 · 4310.1186/s12943-021-01332-8 ↗
28. Nel · Bioact. Mater. · 2023 · 24 · 401
29. Rothe · Adv. Healthcare Mater. · 2024 · 13 · e240026510.1002/adhm.202400265 ↗
30. Gao · Carbohydr. Polym. · 2024 · 345 · 12256910.1016/j.carbpol.2024.122569 ↗
31. Gao · BMC Cancer · 2019 · 19 · 74310.1186/s12885-019-5925-5 ↗
32. Zhang · Cell Death Dis. · 2022 · 13 · 15910.1038/s41419-022-04606-1 ↗
33. Gao · Proc. Natl. Acad. Sci. U. S. A. · 2014 · 111 · 1653210.1073/pnas.1403234111 ↗
34. Moses · Mol. Cancer Res. · 2016 · 14 · 90910.1158/1541-7786.MCR-15-0474 ↗
35. Hu · Nature · 2023 · 616 · 80610.1038/s41586-023-05880-5 ↗
36. Kurppa · Cancer Cell · 2020 · 37 · 10410.1016/j.ccell.2019.12.006 ↗
37. Sun · Sci. Adv. · 2022 · 8 · eabo087610.1126/sciadv.abo0876 ↗
38. Holmgren · Nat. Med. · 1995 · 1 · 14910.1038/nm0295-149 ↗
39. Recasens · Trends Pharmacol. Sci. · 2019 · 40 · 12810.1016/j.tips.2018.12.004 ↗
40. Geiger · J. Clin. Oncol. · 2021 · 39 · 190910.1200/JCO.21.00449 ↗
41. Jahangiri · Int. J. Mol. Sci. · 2022 · 23 · 527110.3390/ijms23095271 ↗
42. Nik Nabil · Cells · 2021 · 10 · 56210.3390/cells10030562 ↗
43. Zhan · Autophagy · 2022 · 18 · 72610.1080/15548627.2021.1954348 ↗
44. Blessing · Cancer · 2020 · 126 · 357910.1002/cncr.32985 ↗
45. White · Sci. Rep. · 2020 · 10 · 1250510.1038/s41598-020-68668-x ↗
46. Gomatou · Int. J. Mol. Sci. · 2021 · 22 · 486210.3390/ijms22094862 ↗
47. Liu · Mol. Cancer · 2017 · 16 · 10610.1186/s12943-017-0669-9 ↗
48. Wang · Acta Crystallogr., Sect. F:Struct. Biol. Cryst. Commun. · 2006 · 62 · 109710.1107/S1744309106037730 ↗
49. Liu · Front. Mol. Biosci. · 2021 · 8 · 60575410.3389/fmolb.2021.605754 ↗
50. Kaushik · Nat. Commun. · 2016 · 7 · 1161210.1038/ncomms11612 ↗
51. He · Biomedicines · 2024 · 12 · 147710.3390/biomedicines12071477 ↗
52. Gerstberger · Cell · 2023 · 186 · 156410.1016/j.cell.2023.03.003 ↗
53. Dashzeveg · Cancer Discovery · 2023 · 13 · 205010.1158/2159-8290.CD-22-0644 ↗
54. Aizik · Acta Biomater. · 2024 · 183 · 10110.1016/j.actbio.2024.05.044 ↗
55. Yang · J. Mater. Chem. B · 2024 · 12 · 517110.1039/D4TB00210E ↗
56. Ramamoorthi · Semin. Cancer Biol. · 2022 · 78 · 7810.1016/j.semcancer.2021.02.004 ↗
57. Li · Sci. Adv. · 2021 · 7 · eabd674010.1126/sciadv.abd6740 ↗